Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 434 entries
Sorted by: Best Match Show Resources per page
Analyzing historical trends in breast cancer biomarker expression: a feasibility study (1947-2009).

NPJ breast cancer

Krieger N, Habel LA, Waterman PD, Shabani M, Ellison-Loschmann L, Achacoso NS, Acton L, Schnitt SJ.
PMID: 26807440
NPJ Breast Cancer. 2015;1. doi: 10.1038/npjbcancer.2015.16. Epub 2015 Oct 07.

BACKGROUND/OBJECTIVES: Determining long-term trends in tumor biomarker expression is essential for understanding aspects of tumor biology amenable to change. Limiting the availability of such data, currently used assays for biomarkers are relatively new. For example, assays for the estrogen...

Cite
Krieger N, Habel LA, Waterman PD, et al. Analyzing historical trends in breast cancer biomarker expression: a feasibility study (1947-2009). NPJ Breast Cancer. 2015;1doi: 10.1038/npjbcancer.2015.16.
Krieger, N., Habel, L. A., Waterman, P. D., Shabani, M., Ellison-Loschmann, L., Achacoso, N. S., Acton, L., & Schnitt, S. J. (2015). Analyzing historical trends in breast cancer biomarker expression: a feasibility study (1947-2009). NPJ breast cancer, 1. https://doi.org/10.1038/npjbcancer.2015.16
Krieger, Nancy, et al. "Analyzing historical trends in breast cancer biomarker expression: a feasibility study (1947-2009)." NPJ breast cancer vol. 1 (2015). doi: https://doi.org/10.1038/npjbcancer.2015.16
Krieger N, Habel LA, Waterman PD, Shabani M, Ellison-Loschmann L, Achacoso NS, Acton L, Schnitt SJ. Analyzing historical trends in breast cancer biomarker expression: a feasibility study (1947-2009). NPJ Breast Cancer. 2015;1. doi: 10.1038/npjbcancer.2015.16. Epub 2015 Oct 07. PMID: 26807440; PMCID: PMC4721558.
Copy Download .nbib Format: NLM
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

NPJ breast cancer

Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.
PMID: 28948212
NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.

Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature. However, not all triple negative patients achieved pathologic complete response...

Cite
Wolf DM, Yau C, Sanil A, et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017;3:31doi: 10.1038/s41523-017-0025-7.
Wolf, D. M., Yau, C., Sanil, A., Glas, A., Petricoin, E., Wulfkuhle, J., Severson, T. M., Linn, S., Brown-Swigart, L., Hirst, G., Buxton, M., DeMichele, A., Hylton, N., Symmans, F., Yee, D., Paoloni, M., Esserman, L., Berry, D., Rugo, H., Olopade, O., & van 't Veer, L. (2017). DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ breast cancer, 331. https://doi.org/10.1038/s41523-017-0025-7
Wolf, Denise M, et al. "DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial." NPJ breast cancer vol. 3 (2017): 31. doi: https://doi.org/10.1038/s41523-017-0025-7
Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017. PMID: 28948212; PMCID: PMC5572474.
Copy Download .nbib Format: NLM
The WISDOM Study: breaking the deadlock in the breast cancer screening debate.

NPJ breast cancer

Esserman LJ.
PMID: 28944288
NPJ Breast Cancer. 2017 Sep 13;3:34. doi: 10.1038/s41523-017-0035-5. eCollection 2017.

There are few medical issues that have generated as much controversy as screening for breast cancer. In science, controversy often stimulates innovation; however, the intensely divisive debate over mammographic screening has had the opposite effect and has stifled progress....

Cite
Esserman LJ. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer. 2017;3:34doi: 10.1038/s41523-017-0035-5.
Esserman, L. J. (2017). The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ breast cancer, 334. https://doi.org/10.1038/s41523-017-0035-5
Esserman, Laura J. "The WISDOM Study: breaking the deadlock in the breast cancer screening debate." NPJ breast cancer vol. 3 (2017): 34. doi: https://doi.org/10.1038/s41523-017-0035-5
Esserman LJ. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer. 2017 Sep 13;3:34. doi: 10.1038/s41523-017-0035-5. eCollection 2017. PMID: 28944288; PMCID: PMC5597574.
Copy Download .nbib Format: NLM
Video intervention increases participation of black breast cancer patients in therapeutic trials.

NPJ breast cancer

Robinson BN, Newman AF, Tefera E, Herbolsheimer P, Nunes R, Gallagher C, Randolph-Jackson P, Omogbehin A, Dilawari A, Pohlmann PR, Mohebtash M, Lee Y, Ottaviano Y, Mohapatra A, Lynce F, Brown R, Mete M, Swain SM.
PMID: 28944289
NPJ Breast Cancer. 2017 Sep 18;3:36. doi: 10.1038/s41523-017-0039-1. eCollection 2017.

There is a striking racial and ethnic disparity in incidence and mortality of cancer yet minorities remain markedly underrepresented in clinical trials. This pilot study set out to determine the impact of a 15-min culturally tailored educational video on...

Cite
Robinson BN, Newman AF, Tefera E, et al. Video intervention increases participation of black breast cancer patients in therapeutic trials. NPJ Breast Cancer. 2017;3:36doi: 10.1038/s41523-017-0039-1.
Robinson, B. N., Newman, A. F., Tefera, E., Herbolsheimer, P., Nunes, R., Gallagher, C., Randolph-Jackson, P., Omogbehin, A., Dilawari, A., Pohlmann, P. R., Mohebtash, M., Lee, Y., Ottaviano, Y., Mohapatra, A., Lynce, F., Brown, R., Mete, M., & Swain, S. M. (2017). Video intervention increases participation of black breast cancer patients in therapeutic trials. NPJ breast cancer, 336. https://doi.org/10.1038/s41523-017-0039-1
Robinson, Brandi N, et al. "Video intervention increases participation of black breast cancer patients in therapeutic trials." NPJ breast cancer vol. 3 (2017): 36. doi: https://doi.org/10.1038/s41523-017-0039-1
Robinson BN, Newman AF, Tefera E, Herbolsheimer P, Nunes R, Gallagher C, Randolph-Jackson P, Omogbehin A, Dilawari A, Pohlmann PR, Mohebtash M, Lee Y, Ottaviano Y, Mohapatra A, Lynce F, Brown R, Mete M, Swain SM. Video intervention increases participation of black breast cancer patients in therapeutic trials. NPJ Breast Cancer. 2017 Sep 18;3:36. doi: 10.1038/s41523-017-0039-1. eCollection 2017. PMID: 28944289; PMCID: PMC5603544.
Copy Download .nbib Format: NLM
Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer.

NPJ breast cancer

Oh H, Eliassen AH, Wang M, Smith-Warner SA, Beck AH, Schnitt SJ, Collins LC, Connolly JL, Montaser-Kouhsari L, Polyak K, Tamimi RM.
PMID: 28111631
NPJ Breast Cancer. 2016;2. doi: 10.1038/npjbcancer.2016.32. Epub 2016 Oct 26.

Although expression of estrogen receptor (ER), progesterone receptor (PR), and cell proliferation marker Ki67 serve as predictive and prognostic factors in breast cancers, little is known about their roles in normal breast tissue. Here in a nested case-control study...

Cite
Oh H, Eliassen AH, Wang M, et al. Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ Breast Cancer. 2016;2doi: 10.1038/npjbcancer.2016.32.
Oh, H., Eliassen, A. H., Wang, M., Smith-Warner, S. A., Beck, A. H., Schnitt, S. J., Collins, L. C., Connolly, J. L., Montaser-Kouhsari, L., Polyak, K., & Tamimi, R. M. (2016). Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ breast cancer, 2. https://doi.org/10.1038/npjbcancer.2016.32
Oh, Hannah, et al. "Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer." NPJ breast cancer vol. 2 (2016). doi: https://doi.org/10.1038/npjbcancer.2016.32
Oh H, Eliassen AH, Wang M, Smith-Warner SA, Beck AH, Schnitt SJ, Collins LC, Connolly JL, Montaser-Kouhsari L, Polyak K, Tamimi RM. Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ Breast Cancer. 2016;2. doi: 10.1038/npjbcancer.2016.32. Epub 2016 Oct 26. PMID: 28111631; PMCID: PMC5243126.
Copy Download .nbib Format: NLM
Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression.

NPJ breast cancer

Abubakar M, Guo C, Koka H, Sung H, Shao N, Guida J, Deng J, Li M, Hu N, Zhou B, Lu N, Yang XR.
PMID: 31372496
NPJ Breast Cancer. 2019 Jul 25;5:20. doi: 10.1038/s41523-019-0117-7. eCollection 2019.

No abstract available.

Cite
Abubakar M, Guo C, Koka H, et al. Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. NPJ Breast Cancer. 2019;5:20doi: 10.1038/s41523-019-0117-7.
Abubakar, M., Guo, C., Koka, H., Sung, H., Shao, N., Guida, J., Deng, J., Li, M., Hu, N., Zhou, B., Lu, N., & Yang, X. R. (2019). Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. NPJ breast cancer, 520. https://doi.org/10.1038/s41523-019-0117-7
Abubakar, Mustapha, et al. "Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression." NPJ breast cancer vol. 5 (2019): 20. doi: https://doi.org/10.1038/s41523-019-0117-7
Abubakar M, Guo C, Koka H, Sung H, Shao N, Guida J, Deng J, Li M, Hu N, Zhou B, Lu N, Yang XR. Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. NPJ Breast Cancer. 2019 Jul 25;5:20. doi: 10.1038/s41523-019-0117-7. eCollection 2019. PMID: 31372496; PMCID: PMC6658470.
Copy Download .nbib Format: NLM
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

NPJ breast cancer

Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ.
PMID: 30675512
NPJ Breast Cancer. 2019 Jan 02;5:2. doi: 10.1038/s41523-018-0096-0. eCollection 2019.

[This corrects the article DOI: 10.1038/s41523-018-0074-6.].

Cite
Boughey JC, Alvarado MD, Lancaster RB, et al. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ Breast Cancer. 2019;5:2doi: 10.1038/s41523-018-0096-0.
Boughey, J. C., Alvarado, M. D., Lancaster, R. B., Symmans, W. F., Mukhtar, R., Wong, J. M., Ewing, C. A., Potter, D. A., Tuttle, T. M., Hieken, T. J., Carter, J. M., Jakub, J. W., Kaplan, H. G., Buchanan, C. L., Jaskowiak, N. T., Sattar, H. A., Mueller, J., Nanda, R., Isaacs, C. J., Pohlmann, P. R., Lynce, F., Tousimis, E. A., Zeck, J. C., Lee, M. C., Lang, J. E., Mhawech-Fauceglia, P., Rao, R., Taback, B., Goodellas, C., Chen, M., Kalinsky, K. M., Hibshoosh, H., Killelea, B., Sanft, T., Hirst, G. L., Asare, S., Matthews, J. B., Perlmutter, J., Esserman, L. J. (2019). Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ breast cancer, 52. https://doi.org/10.1038/s41523-018-0096-0
Boughey, Judy C, et al. "Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint." NPJ breast cancer vol. 5 (2019): 2. doi: https://doi.org/10.1038/s41523-018-0096-0
Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ Breast Cancer. 2019 Jan 02;5:2. doi: 10.1038/s41523-018-0096-0. eCollection 2019. PMID: 30675512; PMCID: PMC6315027.
Copy Download .nbib Format: NLM
AKT1.

NPJ breast cancer

Kabraji S, Sole X, Huang Y, Bango C, Sgroi D, Loda M, Ramaswamy S.
PMID: 30911675
NPJ Breast Cancer. 2019 Mar 21;5:10. doi: 10.1038/s41523-019-0105-y. eCollection 2019.

Ductal carcinoma in situ (DCIS) of the breast precedes the development of invasive breast cancer and reflects the genomic changes and protein expression profile of invasive disease. AKT1

Cite
Kabraji S, Sole X, Huang Y, et al. AKT1. NPJ Breast Cancer. 2019;5:10doi: 10.1038/s41523-019-0105-y.
Kabraji, S., Sole, X., Huang, Y., Bango, C., Sgroi, D., Loda, M., & Ramaswamy, S. (2019). AKT1. NPJ breast cancer, 510. https://doi.org/10.1038/s41523-019-0105-y
Kabraji, Sheheryar, et al. "AKT1." NPJ breast cancer vol. 5 (2019): 10. doi: https://doi.org/10.1038/s41523-019-0105-y
Kabraji S, Sole X, Huang Y, Bango C, Sgroi D, Loda M, Ramaswamy S. AKT1. NPJ Breast Cancer. 2019 Mar 21;5:10. doi: 10.1038/s41523-019-0105-y. eCollection 2019. PMID: 30911675; PMCID: PMC6428812.
Copy Download .nbib Format: NLM
Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer.

NPJ breast cancer

Schroeder B, Zhang Y, Stål O, Fornander T, Brufsky A, Sgroi DC, Schnabel CA.
PMID: 28795152
NPJ Breast Cancer. 2017 Aug 03;3:28. doi: 10.1038/s41523-017-0037-3. eCollection 2017.

Patients with early-stage, hormone receptor-positive breast cancer with favorable clinicopathologic features are often not recommended for extended endocrine therapy. However, even patients with T1N0 disease remain at significant risk of distant recurrence up to 15 years following 5 years...

Cite
Schroeder B, Zhang Y, Stål O, et al. Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. NPJ Breast Cancer. 2017;3:28doi: 10.1038/s41523-017-0037-3.
Schroeder, B., Zhang, Y., Stål, O., Fornander, T., Brufsky, A., Sgroi, D. C., & Schnabel, C. A. (2017). Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. NPJ breast cancer, 328. https://doi.org/10.1038/s41523-017-0037-3
Schroeder, Brock, et al. "Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer." NPJ breast cancer vol. 3 (2017): 28. doi: https://doi.org/10.1038/s41523-017-0037-3
Schroeder B, Zhang Y, Stål O, Fornander T, Brufsky A, Sgroi DC, Schnabel CA. Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. NPJ Breast Cancer. 2017 Aug 03;3:28. doi: 10.1038/s41523-017-0037-3. eCollection 2017. PMID: 28795152; PMCID: PMC5543049.
Copy Download .nbib Format: NLM
Breast cancer survivors are at an increased risk for osteoporotic fractures not explained by lower BMD: a retrospective analysis.

NPJ breast cancer

Fraenkel M, Geffen DB, Novack V, Shafat T, Mizrakli Y, Ariad S, Koretz M, Norton L, Siris E.
PMID: 28721367
NPJ Breast Cancer. 2015 Jul 22;1:15010. doi: 10.1038/npjbcancer.2015.10. eCollection 2015.

BACKGROUND: An association between higher bone mineral density (BMD) and the diagnosis of breast cancer (BC) has been reported. Data on the risk of osteoporotic fractures in women with BC are conflicting.AIMS: The objective of this study was to...

Cite
Fraenkel M, Geffen DB, Novack V, et al. Breast cancer survivors are at an increased risk for osteoporotic fractures not explained by lower BMD: a retrospective analysis. NPJ Breast Cancer. 2015;1:15010doi: 10.1038/npjbcancer.2015.10.
Fraenkel, M., Geffen, D. B., Novack, V., Shafat, T., Mizrakli, Y., Ariad, S., Koretz, M., Norton, L., & Siris, E. (2015). Breast cancer survivors are at an increased risk for osteoporotic fractures not explained by lower BMD: a retrospective analysis. NPJ breast cancer, 115010. https://doi.org/10.1038/npjbcancer.2015.10
Fraenkel, Merav, et al. "Breast cancer survivors are at an increased risk for osteoporotic fractures not explained by lower BMD: a retrospective analysis." NPJ breast cancer vol. 1 (2015): 15010. doi: https://doi.org/10.1038/npjbcancer.2015.10
Fraenkel M, Geffen DB, Novack V, Shafat T, Mizrakli Y, Ariad S, Koretz M, Norton L, Siris E. Breast cancer survivors are at an increased risk for osteoporotic fractures not explained by lower BMD: a retrospective analysis. NPJ Breast Cancer. 2015 Jul 22;1:15010. doi: 10.1038/npjbcancer.2015.10. eCollection 2015. PMID: 28721367; PMCID: PMC5515201.
Copy Download .nbib Format: NLM
Breast cancer cell adhesome and degradome interact to drive metastasis.

NPJ breast cancer

Rizwan A, Cheng M, Bhujwalla ZM, Krishnamachary B, Jiang L, Glunde K.
PMID: 28721370
NPJ Breast Cancer. 2015 Oct 28;1:15017. doi: 10.1038/npjbcancer.2015.17. eCollection 2015.

BACKGROUND: Although primary breast tumors are detected early in most cases, it is inevitable that many patients remain at risk for future recurrence and death due to micrometastases. We investigated interactions between the degradome and the adhesome that drive...

Cite
Rizwan A, Cheng M, Bhujwalla ZM, et al. Breast cancer cell adhesome and degradome interact to drive metastasis. NPJ Breast Cancer. 2015;1:15017doi: 10.1038/npjbcancer.2015.17.
Rizwan, A., Cheng, M., Bhujwalla, Z. M., Krishnamachary, B., Jiang, L., & Glunde, K. (2015). Breast cancer cell adhesome and degradome interact to drive metastasis. NPJ breast cancer, 115017. https://doi.org/10.1038/npjbcancer.2015.17
Rizwan, Asif, et al. "Breast cancer cell adhesome and degradome interact to drive metastasis." NPJ breast cancer vol. 1 (2015): 15017. doi: https://doi.org/10.1038/npjbcancer.2015.17
Rizwan A, Cheng M, Bhujwalla ZM, Krishnamachary B, Jiang L, Glunde K. Breast cancer cell adhesome and degradome interact to drive metastasis. NPJ Breast Cancer. 2015 Oct 28;1:15017. doi: 10.1038/npjbcancer.2015.17. eCollection 2015. PMID: 28721370; PMCID: PMC5515192.
Copy Download .nbib Format: NLM
TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients.

NPJ breast cancer

Comen E, Wojnarowicz P, Seshan VE, Shah R, Coker C, Norton L, Benezra R.
PMID: 28721376
NPJ Breast Cancer. 2016 Apr 20;2:16009. doi: 10.1038/npjbcancer.2016.9. eCollection 2016.

We have previously shown a novel antimetastatic role for neutrophils in the premetastatic lung of mice in models of breast cancer. Here we expand on those findings in the context of human breast cancer. We assessed the cytotoxicity of...

Cite
Comen E, Wojnarowicz P, Seshan VE, et al. TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients. NPJ Breast Cancer. 2016;2:16009doi: 10.1038/npjbcancer.2016.9.
Comen, E., Wojnarowicz, P., Seshan, V. E., Shah, R., Coker, C., Norton, L., & Benezra, R. (2016). TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients. NPJ breast cancer, 216009. https://doi.org/10.1038/npjbcancer.2016.9
Comen, Elizabeth, et al. "TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients." NPJ breast cancer vol. 2 (2016): 16009. doi: https://doi.org/10.1038/npjbcancer.2016.9
Comen E, Wojnarowicz P, Seshan VE, Shah R, Coker C, Norton L, Benezra R. TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients. NPJ Breast Cancer. 2016 Apr 20;2:16009. doi: 10.1038/npjbcancer.2016.9. eCollection 2016. PMID: 28721376; PMCID: PMC5515342.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 434 entries